-transparent.png){kind=logo}
The debrisoquine/sparteine phenotype was determined in 51 patients with depression, who were subdivided into 3 groups in terms of their drug treatment. Log (MR) for each group was compared. Patients treated with benzodiazepines had the same distribution of log (MR) as the healthy population, but the distribution was shifted towards higher values in patients treated with neuroleptics and antidepressants. It appears that the phenotypic expression of debrisoquine oxidation may be modified by drugs whose metabolism follows the same route as debrisoquine. The debrisoquine test must be carefully interpreted in patients receiving several drugs in the same time.
Related Publications
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
January 1991,
Therapie,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
January 1992,
Psychopharmacology bulletin,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
January 1988,
European journal of clinical pharmacology,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
December 1990,
Die Pharmazie,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
November 1989,
Therapeutic drug monitoring,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
September 1990,
Lancet (London, England),
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
October 1990,
Journal of the National Cancer Institute,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
January 1989,
Psychopharmacology series,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
April 2006,
Nature,
F Derenne, and
C Joanne, and
S Vandel, and
G Bertschy, and
R Volmat, and
P Bechtel
August 1999,
Pharmacogenetics,
